Who are Nitric Oxide plus Oxygen's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Inhaled Nitric Oxide (iNO) use, Crossover iNO, iNO.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nitric-oxide-plus-oxygen.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Nitric Oxide plus Oxygen — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nitric Oxide plus Oxygen (Nitric Oxide plus Oxygen) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inhaled vasodilator. Area: Cardiovascular / Pulmonary.

phase 3 Inhaled vasodilator Soluble guanylate cyclase / cGMP pathway Cardiovascular / Pulmonary Small molecule Live · refreshed every 30 min

Target snapshot

Nitric Oxide plus Oxygen (Nitric Oxide plus Oxygen) — Mallinckrodt. Nitric oxide gas combined with oxygen improves oxygenation and vasodilation in the lungs to reduce pulmonary hypertension and improve gas exchange.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Nitric Oxide plus Oxygen TARGET	Nitric Oxide plus Oxygen	Mallinckrodt	phase 3	Inhaled vasodilator	Soluble guanylate cyclase / cGMP pathway
Inhaled Nitric Oxide (iNO) use	Inhaled Nitric Oxide (iNO) use	The University of Texas Health Science Center, Houston	marketed	Inhaled vasodilator	Soluble guanylate cyclase
Crossover iNO	Crossover iNO	University of Florida	marketed	Inhaled vasodilator	Soluble guanylate cyclase (via nitric oxide signaling)
iNO	iNO	Wake Forest University Health Sciences	marketed	Inhaled vasodilator	Soluble guanylate cyclase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inhaled vasodilator class)

Mallinckrodt · 1 drug in this class
The University of Texas Health Science Center, Houston · 1 drug in this class
University of Florida · 1 drug in this class
Wake Forest University Health Sciences · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nitric Oxide plus Oxygen — Competitive Intelligence Brief. https://druglandscape.com/ci/nitric-oxide-plus-oxygen. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing